SG11201605810WA - Benzimidazol-2-amines as midh1 inhibitors - Google Patents
Benzimidazol-2-amines as midh1 inhibitorsInfo
- Publication number
- SG11201605810WA SG11201605810WA SG11201605810WA SG11201605810WA SG11201605810WA SG 11201605810W A SG11201605810W A SG 11201605810WA SG 11201605810W A SG11201605810W A SG 11201605810WA SG 11201605810W A SG11201605810W A SG 11201605810WA SG 11201605810W A SG11201605810W A SG 11201605810WA
- Authority
- SG
- Singapore
- Prior art keywords
- benzimidazol
- amines
- midh1
- inhibitors
- midh1 inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14154680 | 2014-02-11 | ||
EP14182002 | 2014-08-22 | ||
PCT/EP2015/052676 WO2015121210A1 (fr) | 2014-02-11 | 2015-02-10 | Benzimidazol-2-amines en tant qu'inhibiteurs midh1 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201605810WA true SG11201605810WA (en) | 2016-08-30 |
Family
ID=52462928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201605810WA SG11201605810WA (en) | 2014-02-11 | 2015-02-10 | Benzimidazol-2-amines as midh1 inhibitors |
Country Status (23)
Country | Link |
---|---|
US (2) | US9957235B2 (fr) |
EP (1) | EP3105209B1 (fr) |
JP (1) | JP6534675B2 (fr) |
KR (1) | KR20160115991A (fr) |
CN (1) | CN106573897B (fr) |
AP (1) | AP2016009371A0 (fr) |
AU (1) | AU2015217788B2 (fr) |
BR (1) | BR112016018604A2 (fr) |
CA (1) | CA2939026A1 (fr) |
CL (1) | CL2016002033A1 (fr) |
CR (1) | CR20160361A (fr) |
CU (1) | CU24410B1 (fr) |
DO (1) | DOP2016000208A (fr) |
EA (1) | EA031655B1 (fr) |
IL (1) | IL246785A0 (fr) |
MX (1) | MX2016010474A (fr) |
PE (1) | PE20170143A1 (fr) |
PH (1) | PH12016501581A1 (fr) |
SG (1) | SG11201605810WA (fr) |
SV (1) | SV2016005257A (fr) |
TW (1) | TWI666202B (fr) |
UY (1) | UY35991A (fr) |
WO (1) | WO2015121210A1 (fr) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3105210B1 (fr) | 2014-02-11 | 2019-01-30 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines comme inhibiteurs de midh1 |
AP2016009371A0 (en) | 2014-02-11 | 2016-08-31 | Bayer Pharma AG | Benzimidazol-2-amines as midh1 inhibitors |
CA2961793C (fr) | 2014-09-19 | 2021-03-16 | Forma Therapeutics, Inc. | Compositions de quinoleinone pyrimidines en tant qu'inhibiteurs d'isocitrate deshydrogenase mutante |
TWI686390B (zh) | 2014-09-19 | 2020-03-01 | 美商弗瑪治療公司 | 作為突變型異檸檬酸去氫酶抑制劑的吡啶-2(1h)-酮喹啉酮衍生物 |
US10137110B2 (en) | 2014-10-23 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors |
EP3209646B1 (fr) * | 2014-10-23 | 2020-07-22 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Benzimidazol-2-amines en tant qu'inhibiteurs midh1 |
CA2988356A1 (fr) | 2015-06-08 | 2016-12-15 | Bayer Pharma Aktiengesellschaft | N-menthylbenzimidazoles a titre d'inhibiteurs de midh1 |
ES2877424T3 (es) * | 2015-07-07 | 2021-11-16 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | 2-Aril- y 2-arilalquil-bencimidazoles como inhibidores de MIDH1 |
CN108026052B (zh) * | 2015-07-16 | 2021-10-08 | 德国癌症研究公共权益基金会 | 作为mIDH1抑制剂的5-羟烷基苯并咪唑类 |
EP3121166A1 (fr) * | 2015-07-21 | 2017-01-25 | Bayer Pharma Aktiengesellschaft | Imidazoles condensés comme inhibiteurs midh1 |
TW201708193A (zh) | 2015-07-27 | 2017-03-01 | 拜耳製藥公司 | 突變之異檸檬酸脫氫酶idh1 r132h之抑制劑 |
TW201718513A (zh) * | 2015-07-27 | 2017-06-01 | 拜耳製藥公司 | 製備經取代之3-(2-苯胺-1-環己基-1h-苯并咪唑-5-基)丙酸衍生物之方法 |
CA3012133A1 (fr) * | 2016-02-09 | 2017-08-17 | Inventisbio Inc. | Inhibiteur de l'indoleamine-2,3-dioxygenase (ido) |
WO2019015672A1 (fr) * | 2017-07-21 | 2019-01-24 | 南京明德新药研发股份有限公司 | Composé de pyridoimidazole et son utilisation |
EP3661559A1 (fr) * | 2017-08-01 | 2020-06-10 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Combinaison d'inhibiteurs de midh1 et d'agents d'hypométhylation (ahm) d'adn |
US11013733B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
EP3720442B1 (fr) | 2018-05-16 | 2022-12-28 | Forma Therapeutics, Inc. | Inhibition de l'idh-1 mutante |
US11311527B2 (en) | 2018-05-16 | 2022-04-26 | Forma Therapeutics, Inc. | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
US10532047B2 (en) | 2018-05-16 | 2020-01-14 | Forma Therapeutics, Inc. | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
US11013734B2 (en) | 2018-05-16 | 2021-05-25 | Forma Therapeutics, Inc. | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
EP3816158B1 (fr) * | 2018-06-26 | 2023-10-25 | KPC Pharmaceuticals, Inc. | Dérivés de benzimidazole et leur utilisation en tant qu'inhibiteurs d'idh1 |
TWI760017B (zh) * | 2019-12-23 | 2022-04-01 | 大陸商昆藥集團股份有限公司 | 一種idh1突變體抑制劑的鹽型、晶型及其製備方法 |
US12014835B2 (en) | 2020-02-19 | 2024-06-18 | Vanderbilt University | Methods for evaluating therapeutic benefit of combination therapies |
BR112022026634A2 (pt) * | 2020-07-21 | 2023-01-31 | Daiichi Sankyo Co Ltd | Combinação farmacêutica de temozolomida e inibidor da enzima idh1 mutante |
CN112062687B (zh) * | 2020-09-02 | 2023-11-21 | 上海信谊万象药业股份有限公司 | 一种盐酸阿扎司琼中间体3-氨基-5-氯-2-羟基苯甲酸甲酯的合成方法 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2643903A1 (fr) | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux |
CN1161340C (zh) | 1998-11-30 | 2004-08-11 | 先灵公司 | 为玻连蛋白受体拮抗剂的苯并咪唑化合物 |
US6340681B1 (en) | 1999-07-16 | 2002-01-22 | Pfizer Inc | 2-benzimidazolylamine compounds as ORL-1-receptor agonists |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
US7030150B2 (en) | 2001-05-11 | 2006-04-18 | Trimeris, Inc. | Benzimidazole compounds and antiviral uses thereof |
JP4558314B2 (ja) | 2001-07-20 | 2010-10-06 | ベーリンガー インゲルハイム (カナダ) リミテッド | ウイルスポリメラーゼインヒビター |
EP1487824B1 (fr) | 2002-03-01 | 2007-06-20 | SmithKline Beecham Corporation | Diamino-pyrimidines et leurs utilisations en tant qu'inhibiteurs de l'angiogenese |
US7531553B2 (en) | 2003-03-21 | 2009-05-12 | Amgen Inc. | Heterocyclic compounds and methods of use |
CA2543707A1 (fr) | 2003-10-31 | 2005-05-19 | Takeda Pharmaceutical Company Limited | Composes heterocycliques accoles contenant de l'azote |
WO2005121132A1 (fr) | 2004-06-11 | 2005-12-22 | Shionogi & Co., Ltd. | Composé hétérocyclique fondu ayant un effet anti-vhc |
CA2583326A1 (fr) | 2004-10-08 | 2006-04-13 | Takeda Pharmaceutical Company Limited | Agent de regulation du fonctionnement d'un recepteur |
ZA200707896B (en) | 2005-03-14 | 2009-07-29 | High Point Pharma Llc | Benzazole derivatives, compositions, and methods of use as B-secretase inhibitors |
WO2008153701A1 (fr) * | 2007-05-24 | 2008-12-18 | Schering Corporation | Composés d'inhibition de l'activité de ksp kinésine |
WO2009059214A1 (fr) | 2007-11-02 | 2009-05-07 | The Regents Of The University Of California | Petites molécules se liant à abeta |
WO2009116074A2 (fr) | 2008-02-13 | 2009-09-24 | Cadila Healthcare Limited | Benzimidazoles substitués en tant que modulateur cannabinoïde |
UY32138A (es) | 2008-09-25 | 2010-04-30 | Boehringer Ingelheim Int | Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables |
UY32470A (es) | 2009-03-05 | 2010-10-29 | Boehringer Ingelheim Int | Derivados de 2-{2-cloro-5-[(sustituido) metil]fenilamino} -1-metil]fenilamino}-1-metilbencimidazol-5-carboxamidas-n-(sustituidas) y sus sales fisiológicamente aceptables, composiciones conteniéndolos y aplicaciones |
JP5868851B2 (ja) * | 2009-06-23 | 2016-02-24 | ザ・トランスレーショナル・ジェノミクス・リサーチ・インスティチュート | ベンズアミド誘導体 |
ES2642109T3 (es) | 2009-12-09 | 2017-11-15 | Agios Pharmaceuticals, Inc. | Compuestos terapéuticamente activos para su uso en el tratamiento de cáncer caracterizados por tener una mutación de IDH |
WO2012172043A1 (fr) * | 2011-06-15 | 2012-12-20 | Laboratoire Biodim | Dérivés de purine et leur utilisation comme produits pharmaceutiques pour prévenir ou traiter les infections bactériennes |
CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
CN103435554A (zh) * | 2013-09-06 | 2013-12-11 | 中国药科大学 | 2-苯氨基苯并咪唑类化合物及其用途 |
EP3105210B1 (fr) | 2014-02-11 | 2019-01-30 | Bayer Pharma Aktiengesellschaft | Benzimidazol-2-amines comme inhibiteurs de midh1 |
AP2016009371A0 (en) | 2014-02-11 | 2016-08-31 | Bayer Pharma AG | Benzimidazol-2-amines as midh1 inhibitors |
US10137110B2 (en) | 2014-10-23 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | 1-cyclohexyl-2-phenylaminobenzimidazoles as mIDH1 inhibitors for the treatment of tumors |
EP3209646B1 (fr) | 2014-10-23 | 2020-07-22 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Benzimidazol-2-amines en tant qu'inhibiteurs midh1 |
JP2018515623A (ja) | 2015-05-18 | 2018-06-14 | トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー | キナーゼ阻害剤としての複素環式化合物 |
AU2016267059B2 (en) | 2015-05-22 | 2020-08-13 | Translational Drug Development Llc | Benzamide and active compound compositions and methods of use |
CA2988356A1 (fr) | 2015-06-08 | 2016-12-15 | Bayer Pharma Aktiengesellschaft | N-menthylbenzimidazoles a titre d'inhibiteurs de midh1 |
ES2877424T3 (es) | 2015-07-07 | 2021-11-16 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | 2-Aril- y 2-arilalquil-bencimidazoles como inhibidores de MIDH1 |
CN108026052B (zh) | 2015-07-16 | 2021-10-08 | 德国癌症研究公共权益基金会 | 作为mIDH1抑制剂的5-羟烷基苯并咪唑类 |
EP3121166A1 (fr) | 2015-07-21 | 2017-01-25 | Bayer Pharma Aktiengesellschaft | Imidazoles condensés comme inhibiteurs midh1 |
TW201718513A (zh) | 2015-07-27 | 2017-06-01 | 拜耳製藥公司 | 製備經取代之3-(2-苯胺-1-環己基-1h-苯并咪唑-5-基)丙酸衍生物之方法 |
TW201708193A (zh) | 2015-07-27 | 2017-03-01 | 拜耳製藥公司 | 突變之異檸檬酸脫氫酶idh1 r132h之抑制劑 |
CA3053238A1 (fr) | 2016-03-02 | 2017-09-08 | Translational Drug Development Llc | Derives d'aminobenzimidazole |
-
2015
- 2015-02-10 AP AP2016009371A patent/AP2016009371A0/en unknown
- 2015-02-10 KR KR1020167024825A patent/KR20160115991A/ko not_active Application Discontinuation
- 2015-02-10 AU AU2015217788A patent/AU2015217788B2/en not_active Ceased
- 2015-02-10 US US15/118,154 patent/US9957235B2/en active Active
- 2015-02-10 BR BR112016018604A patent/BR112016018604A2/pt not_active Application Discontinuation
- 2015-02-10 JP JP2016551221A patent/JP6534675B2/ja not_active Expired - Fee Related
- 2015-02-10 CU CU2016000120A patent/CU24410B1/es unknown
- 2015-02-10 CN CN201580019265.9A patent/CN106573897B/zh not_active Expired - Fee Related
- 2015-02-10 EA EA201691590A patent/EA031655B1/ru not_active IP Right Cessation
- 2015-02-10 CR CR20160361A patent/CR20160361A/es unknown
- 2015-02-10 WO PCT/EP2015/052676 patent/WO2015121210A1/fr active Application Filing
- 2015-02-10 CA CA2939026A patent/CA2939026A1/fr not_active Abandoned
- 2015-02-10 EP EP15703288.9A patent/EP3105209B1/fr active Active
- 2015-02-10 PE PE2016001465A patent/PE20170143A1/es unknown
- 2015-02-10 MX MX2016010474A patent/MX2016010474A/es unknown
- 2015-02-10 SG SG11201605810WA patent/SG11201605810WA/en unknown
- 2015-02-11 UY UY0001035991A patent/UY35991A/es not_active Application Discontinuation
- 2015-02-11 TW TW104104623A patent/TWI666202B/zh not_active IP Right Cessation
-
2016
- 2016-07-14 IL IL246785A patent/IL246785A0/en unknown
- 2016-08-10 PH PH12016501581A patent/PH12016501581A1/en unknown
- 2016-08-11 CL CL2016002033A patent/CL2016002033A1/es unknown
- 2016-08-11 DO DO2016000208A patent/DOP2016000208A/es unknown
- 2016-08-11 SV SV2016005257A patent/SV2016005257A/es unknown
-
2018
- 2018-03-16 US US15/923,895 patent/US10442772B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2939026A1 (fr) | 2015-08-20 |
PH12016501581A1 (en) | 2017-02-06 |
TW201613874A (en) | 2016-04-16 |
KR20160115991A (ko) | 2016-10-06 |
TWI666202B (zh) | 2019-07-21 |
CN106573897B (zh) | 2019-09-24 |
SV2016005257A (es) | 2018-10-02 |
WO2015121210A1 (fr) | 2015-08-20 |
MX2016010474A (es) | 2016-10-31 |
US9957235B2 (en) | 2018-05-01 |
AU2015217788B2 (en) | 2019-06-27 |
EP3105209B1 (fr) | 2019-08-21 |
BR112016018604A2 (pt) | 2017-08-08 |
EP3105209A1 (fr) | 2016-12-21 |
CL2016002033A1 (es) | 2017-03-31 |
JP6534675B2 (ja) | 2019-06-26 |
US10442772B2 (en) | 2019-10-15 |
US20190062285A1 (en) | 2019-02-28 |
US20170197921A1 (en) | 2017-07-13 |
JP2017505790A (ja) | 2017-02-23 |
CR20160361A (es) | 2016-10-03 |
CU24410B1 (es) | 2019-05-03 |
AP2016009371A0 (en) | 2016-08-31 |
EA201691590A1 (ru) | 2017-02-28 |
CU20160120A7 (es) | 2016-12-23 |
DOP2016000208A (es) | 2016-09-15 |
AU2015217788A1 (en) | 2016-08-04 |
EA031655B1 (ru) | 2019-02-28 |
UY35991A (es) | 2015-09-30 |
IL246785A0 (en) | 2016-08-31 |
PE20170143A1 (es) | 2017-03-19 |
CN106573897A (zh) | 2017-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL287113A (en) | smyd inhibitors | |
IL277167B (en) | Cyclopropylamines as lsd1 inhibitors | |
IL277299B (en) | Cyclopropylamines as lsd1 inhibitors | |
IL246785A0 (en) | Benzimidazole-2-amines as midh1 inhibitors | |
IL251420A0 (en) | Triazolopyrazinones as pde1 inhibitors | |
HK1226398A1 (zh) | 作為midh1抑制劑的苯並咪唑-2-胺 | |
IL251932B (en) | Benzylpropargyl ether as nitrification inhibitors | |
IL248895A0 (en) | Phosphatidylinositol 3-kinase inhibitors | |
EP3183255C0 (fr) | Spiropyrrolidines utiles en tant qu'inhibiteurs de mdm2 | |
SG11201609350XA (en) | Methods for inhibiting necroptosis | |
GB201403536D0 (en) | Inhibitor compounds | |
GB201501004D0 (en) | Inhibitors | |
HUE045220T2 (hu) | Imidazopiridazin-származékok mint PI3Kbéta inhibitorok | |
HK1232214A1 (zh) | 作為 抑制劑的六氫呋喃並吡咯 | |
GB201401005D0 (en) | Inhibitor | |
GB201520949D0 (en) | Inhibitors | |
GB201418154D0 (en) | Inhibitors | |
GB201407585D0 (en) | SMA-Inter Act |